$CRDL — Major expansion for Cardiol Therapeutics’ MAVERIC Phase III trial — top U.S. centers now enrolling and patient enrollment >50%. More sites expected. Full story: https://wix.to/4lK5sM6 #MAVERIC #CardiolTherapeutics #ClinicalTrials #Biotech @frontpagestocks